These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 19116379)

  • 1. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity.
    Hellberg V; Wallin I; Eriksson S; Hernlund E; Jerremalm E; Berndtsson M; Eksborg S; Arnér ES; Shoshan M; Ehrsson H; Laurell G
    J Natl Cancer Inst; 2009 Jan; 101(1):37-47. PubMed ID: 19116379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cochlear pharmacokinetics of cisplatin: an in vivo study in the guinea pig.
    Hellberg V; Wallin I; Ehrsson H; Laurell G
    Laryngoscope; 2013 Dec; 123(12):3172-7. PubMed ID: 23754209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents.
    Gersten BK; Fitzgerald TS; Fernandez KA; Cunningham LL
    J Assoc Res Otolaryngol; 2020 Aug; 21(4):303-321. PubMed ID: 32583132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood flow-independent accumulation of cisplatin in the guinea pig cochlea.
    Miettinen S; Laurell G; Andersson A; Johansson R; Laurikainen E
    Acta Otolaryngol; 1997 Jan; 117(1):55-60. PubMed ID: 9039482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin and oxaliplatin are toxic to cochlear outer hair cells and both target thioredoxin reductase in organ of Corti cultures.
    Dammeyer P; Hellberg V; Wallin I; Laurell G; Shoshan M; Ehrsson H; Arnér ES; Kirkegaard M
    Acta Otolaryngol; 2014 May; 134(5):448-54. PubMed ID: 24702224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ototoxicity of the new platinum anticancer agent TRK-710 in comparison with cisplatin.
    Saito T; Manabe Y; Saito H
    ORL J Otorhinolaryngol Relat Spec; 1995; 57(5):250-5. PubMed ID: 8587776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar pharmacokinetics and differential ototoxicity after administration with cisplatin and transplatin in guinea pigs.
    Saito T; Zhang ZJ; Yamada T; Yamamoto T; Shibamori Y; Saito H
    Acta Otolaryngol; 1997 Jan; 117(1):61-5. PubMed ID: 9039483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of ototoxic drugs on mechano-electric transduction channels in chick cochlear hair cells.
    Kimitsuki T; Nakagawa T; Hisashi K; Komune S; Uemura T
    Eur Arch Otorhinolaryngol; 1994; 251 Suppl 1():S53-6. PubMed ID: 11894776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis.
    Cashin PH; Ehrsson H; Wallin I; Nygren P; Mahteme H
    Eur J Clin Pharmacol; 2013 Mar; 69(3):533-40. PubMed ID: 22983312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents.
    Schweitzer VG
    Laryngoscope; 1993 Apr; 103(4 Pt 2):1-52. PubMed ID: 8464301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of platinum in blood and perilymph in relation to cisplatin induced ototoxicity in the guinea pig.
    Sepmeijer JW; Klis SF
    Hear Res; 2009 Jan; 247(1):34-9. PubMed ID: 18955125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents.
    Perde-Schrepler M; Fischer-Fodor E; Virag P; Brie I; Cenariu M; Pop C; Valcan A; Gurzau E; Maniu A
    Hear Res; 2020 Mar; 388():107893. PubMed ID: 32006874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat.
    Los G; Mutsaers PH; Ruevekamp M; McVie JG
    Cancer Lett; 1990 May; 51(2):109-17. PubMed ID: 2344588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies.
    Pestieau SR; Belliveau JF; Griffin H; Stuart OA; Sugarbaker PH
    J Surg Oncol; 2001 Feb; 76(2):106-14. PubMed ID: 11223836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients.
    Burz C; Berindan-Neagoe IB; Balacescu O; Tanaselia C; Ursu M; Gog A; Vlase L; Chintoanu M; Balacescu L; Leucuta SE; Irimie A; Cristea V
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):39-43. PubMed ID: 19337632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ototoxicity among cisplatin, carboplatin, and oxaliplatin in zebrafish model.
    Li KH; Zhao YY; Cheng HL; Yang JJ; Chien CY
    Environ Toxicol; 2024 Jul; 39(7):4058-4065. PubMed ID: 38661261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals.
    Dehne N; Lautermann J; Petrat F; Rauen U; de Groot H
    Toxicol Appl Pharmacol; 2001 Jul; 174(1):27-34. PubMed ID: 11437646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of cisplatin in perilymph and cerebrospinal fluid after intravenous administration in the guinea pig.
    Laurell G; Andersson A; Engström B; Ehrsson H
    Cancer Chemother Pharmacol; 1995; 36(1):83-6. PubMed ID: 7720182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics and administration of established platinum drugs.
    O'Dwyer PJ; Stevenson JP; Johnson SW
    Drugs; 2000; 59 Suppl 4():19-27. PubMed ID: 10864227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular uptake and cytoplasm / DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116.
    Tippayamontri T; Kotb R; Paquette B; Sanche L
    Invest New Drugs; 2011 Dec; 29(6):1321-7. PubMed ID: 20658169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.